Movement Alert｜CARsgen Therapeutics-B Rises 5.14% in Regular Trading, Buyback Plan and Biotech Sector Strength Fuel Rebound

Market Focus07-03

On July 3, CARsgen Therapeutics-B rose 5.14% in regular trading, trading at HKD 15.85/share, with turnover of HKD 45.27 million.

The rally was driven by the ongoing support from the company's share buyback plan combined with broad-based strength in the biotech sector. The board approved a buyback program on June 25 to repurchase up to approximately 30.12 million shares, representing about 5% of total issued shares, funded from non-IPO proceeds including business development revenue and interest income.

Within the Biotechnology sector, multiple peers posted notable gains on the day, with Akeso up 4.91%, 3SBio up 4.85%, SKB Bio up 4.19%, BeiGene up 3.26%, and Innovent Bio up 1.46%, creating a sector-wide tailwind. The stock had previously experienced a sustained pullback following the landmark approval of its globally first solid tumor CAR-T product Satri-Cel in late June, and the buyback plan coupled with sector recovery continues to provide repair momentum for the near-term trend.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1164001411?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-03 13:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1164001411","market":"us","top_or_hot":-1,"title":"Movement Alert｜CARsgen Therapeutics-B Rises 5.14% in Regular Trading, Buyback Plan and Biotech Sector Strength Fuel Rebound","media":"Market Focus","content":"<p><p>On July 3, CARsgen Therapeutics-B rose 5.14% in regular trading, trading at HKD 15.85/share, with turnover of HKD 45.27 million.</p><p>The rally was driven by the ongoing support from the company's share buyback plan combined with broad-based strength in the biotech sector. The board approved a buyback program on June 25 to repurchase up to approximately 30.12 million shares, representing about 5% of total issued shares, funded from non-IPO proceeds including business development revenue and interest income.</p><p>Within the Biotechnology sector, multiple peers posted notable gains on the day, with Akeso up 4.91%, 3SBio up 4.85%, SKB Bio up 4.19%, BeiGene up 3.26%, and Innovent Bio up 1.46%, creating a sector-wide tailwind. The stock had previously experienced a sustained pullback following the landmark approval of its globally first solid tumor CAR-T product Satri-Cel in late June, and the buyback plan coupled with sector recovery continues to provide repair momentum for the near-term trend.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜CARsgen Therapeutics-B Rises 5.14% in Regular Trading, Buyback Plan and Biotech Sector Strength Fuel Rebound</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜CARsgen Therapeutics-B Rises 5.14% in Regular Trading, Buyback Plan and Biotech Sector Strength Fuel Rebound\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-03 13:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 3, CARsgen Therapeutics-B rose 5.14% in regular trading, trading at HKD 15.85/share, with turnover of HKD 45.27 million.</p><p>The rally was driven by the ongoing support from the company's share buyback plan combined with broad-based strength in the biotech sector. The board approved a buyback program on June 25 to repurchase up to approximately 30.12 million shares, representing about 5% of total issued shares, funded from non-IPO proceeds including business development revenue and interest income.</p><p>Within the Biotechnology sector, multiple peers posted notable gains on the day, with Akeso up 4.91%, 3SBio up 4.85%, SKB Bio up 4.19%, BeiGene up 3.26%, and Innovent Bio up 1.46%, creating a sector-wide tailwind. The stock had previously experienced a sustained pullback following the landmark approval of its globally first solid tumor CAR-T product Satri-Cel in late June, and the buyback plan coupled with sector recovery continues to provide repair momentum for the near-term trend.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02171","symbol_name":"科济药业-B","start_time":0,"source_url":"","article_id":"1164001411","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1164001411","pubTimestamp":1783055627,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 3, CARsgen Therapeutics-B rose 5.14% in regular trading, trading at HKD 15.85/share, with turnover of HKD 45.27 million.The rally was driven by the ongoing support from the company's share...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02171":"科济药业-B"},"translate_title":"走势提示|科济生物-B常规交易涨5.14%回购计划及生物科技板块走强助推反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":1},"content_text":"On July 3, CARsgen Therapeutics-B rose 5.14% in regular trading, trading at HKD 15.85/share, with turnover of HKD 45.27 million.The rally was driven by the ongoing support from the company's share buyback plan combined with broad-based strength in the biotech sector. The board approved a buyback program on June 25 to repurchase up to approximately 30.12 million shares, representing about 5% of total issued shares, funded from non-IPO proceeds including business development revenue and interest income.Within the Biotechnology sector, multiple peers posted notable gains on the day, with Akeso up 4.91%, 3SBio up 4.85%, SKB Bio up 4.19%, BeiGene up 3.26%, and Innovent Bio up 1.46%, creating a sector-wide tailwind. The stock had previously experienced a sustained pullback following the landmark approval of its globally first solid tumor CAR-T product Satri-Cel in late June, and the buyback plan coupled with sector recovery continues to provide repair momentum for the near-term trend.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1164001411","isCrawlerRequest":true}